Import Carbolieva 450mg Injection from India to USA – Ernest Oncology

Comprehensive Guide to Carbolieva 450mg Injection: Global Export & Distribution by Ernest Oncology

At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we are an internationally recognized exporter, bulk supplier, and distributor of critical oncology formulations. We specialize in the secure, compliant, and efficient supply of Carbolieva 450mg Injection (Carboplatin Injection USP 450 mg/45 mL) to healthcare providers, hospitals, and pharmaceutical distributors worldwide, with targeted delivery networks in the USA, UK, Australia, and South Africa.

1. Product Information: Carbolieva 450mg Injection

Carbolieva 450mg Injection contains Carboplatin, a second-generation, platinum-based antineoplastic agent. It is utilized for its antineoplastic effects against various solid tumors, providing a favorable toxicity profile compared to older platinum-containing compounds.

Key Product Details

• Composition: Carboplatin USP 450 mg / 45 mL (10 mg/mL).

• Therapeutic Class: Platinum coordination complex / Alkylating agent.

• Formulation Type: Solution for intravenous infusion.

• Storage Temperature: Store below 25°C. Protect from light. Do not freeze.

2. Mechanism of Action

Carbolieva functions as an alkylating agent that interferes with the genetic material of cancer cells:

• DNA Cross-linking: The compound enters the cell and binds to DNA, forming intra-strand and inter-strand cross-links.

• Inhibition of Synthesis: This cross-linking inhibits DNA replication and transcription.

• Apoptosis: The resulting DNA damage triggers programmed cell death (apoptosis) in rapidly dividing malignant cells.

3. Therapeutic Indications and Uses

Carbolieva 450mg Injection is indicated for:

• Ovarian Cancer: First-line and adjunctive therapy for advanced ovarian carcinoma of epithelial origin.

• Small Cell Lung Cancer (SCLC): Used in combination regimens for treating extensive or limited-stage SCLC.

• Other Solid Tumors: Secondary treatments for cervical, bladder, head, and neck cancers.

4. Administration and Safety Warnings

Administration

• Route of Administration: Intravenous (IV) infusion (typically over 15 to 60 minutes) after dilution in 5% Dextrose (D5W) or Normal Saline.

• Compatibility Warning: Do not use needles or intravenous administration sets containing aluminum parts that may react with carboplatin, causing precipitation and loss of potency.

• Dosage Formulation: Administered under the direct supervision of an oncologist, with dosage typically calculated based on the Calvert formula (using the patient's renal function and desired AUC).

Side Effects & Precautions

• Common Side Effects: Nausea, vomiting, fatigue, loss of appetite, and alopecia (hair loss).

• Serious Risks: Severe bone marrow suppression (leading to thrombocytopenia, neutropenia, and anemia), nephrotoxicity (kidney damage), ototoxicity, and peripheral neuropathy.

• Contraindications: Hypersensitivity to platinum-containing compounds, severe bone marrow depression, and active bleeding tumors.